Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hybrid webcast to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC) presented earlier that day in a late-breaking oral presentation at the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain.
The webcast will take place on Wednesday, June 29 at 10:00 AM EST (4:00 PM local time) and will include the following speakers:
Formal remarks will be followed by a Q&A session. For those attending in person, the webcast will take place at:
AC Hotel by Marriott Barcelona Forum
Registration for the webcast can be accessed on the Investors section of the Agenus website at investor.agenusbio.com, as well as here. Following the webcast, an archived version will also be available on the website.